1. Background {#sec125140}
=============

Malignancy is one of the most common complications after kidney transplant. It is the second cause of death in kidney transplant recipients ([@A20281R1]). The overall incidence of malignancy after kidney transplant has been reported to be 3 to 5 times higher than general population ([@A20281R2], [@A20281R3]).

An increased incidence of malignant tumors in transplant recipients was recognized as early as in the 1970s, and was ascribed to the administration of immunosuppressive medications ([@A20281R4], [@A20281R5]).

Incidence and type of cancer after kidney transplant vary among centers, countries, and time periods ([@A20281R6]). According to the Cincinnati Transplant Tumor Registry and other reports, the most frequent types of tumors are posttransplant lymphoproliferative disorder (PTLD) and squamous cell carcinoma (lip, cervix, vulva, skin) ([@A20281R7], [@A20281R8]).

All recipients, especially recipients with posttransplant malignancy, are at risk of long-term graft loss. One-year survival of graft after kidney transplant in Iran is 94.7% ([@A20281R9]). Also 1-year graft survival in recipients from living unrelated donors (LURD) and living related donors (LRD) are 85.6% and 97.4%, respectively ([@A20281R10]).

Many studies have investigated the factors related to graft survival in the population of recipients. For example, there are several factors that predict long-term graft loss after transplantation. Recipient factors included age, weight, gender, BMI, race, cause of renal failure, induction therapy, presence of surgical complications, CVD (cardiovascular disease) complications, diabetes, depression, infections, same side transplanted kidney, , known primary disease, use of mycophenolate mofetil, sirolimus and/or calcineurin inhibitors, acute rejection episodes, any treated rejection episode, delayed graft function, Black race, recurrence of glomerular disease, and death with a functioning graft. Donor factors included BMI, creatinine, HLA mismatch, age, gender, race, donor/recipient relationship, and type of operation procedure (open vs. laparoscopic). Also donor factors affecting long-term posttransplant graft survival included age, race, sex, cause of death, cold ischemia time, HLA matching, organs from expanded-criteria donors, and cytomegalovirus (CMV) status ([@A20281R10]-[@A20281R16]).

But, few studies have evaluated graft survival in recipients with posttransplant malignancy. In some of the studies, investigators concluded that the presence of malignancy in some of patients is the main cause of death and graft failure ([@A20281R17]). Other studies suggested that medical complications such as cardiovascular disease (CVD), infection, and malignancy were the most common cause of graft loss ([@A20281R18]-[@A20281R20]).

2. Objectives {#sec125141}
=============

Because of the occurrence of malignancy in this population, graft survival and its associated factors are important. So we designed this study to investigate the risk factors of kidney graft survival after diagnosis of posttransplant malignancy.

3. Patients and Methods {#sec125142}
=======================

We evaluated population of recipients that suffered from malignancy collected by Behzad Einollahi et al. They conducted a multicenter study on 12525 kidney recipients in Iran during 24 years follow-up period since October 1984 to December 2008. They collected 266 (2%) biopsy-proven malignancy cases of 26 different types from 16 Transplant Centers in Iran ([@A20281R21]). Sixteen Transplant Centers were located in cities of Tehran, Ahvaz, Zanjan, Mashhad, Babol, Isfahan, Kermanshah, Kerman, Rasht, Urmia, Tabriz, and Shiraz. The patients were taken as a census from 16 Transplant Centers in Iran. In this historical cohort study, 266 cases with posttransplant malignancy were followed up from diagnosis of malignancy until long-term graft loss or the date of their last visit. Patients with other organ transplants, history of previous malignancy and transplantation from deceased donors with the history of malignancy were excluded from the study. This study was approved by the Ethics Committee of Baqiyatallah University of Medical Sciences (code: 35, date: March 10, 2014).

The purpose of our study was to evaluate risk factors associated with survival of the graft. To this effect, by using the univariate analysis, at first we compared incidence of graft loss at the level of covariates by Chi-square test, Fisher exact test, and t test. The significance level was set at P \<0.05. Quantitative and qualitative variables were expressed as mean ± SD and percentage, respectively. In continuation, a Cox proportional hazards model was performed by SPSS version 20 to determine the important independent predictors of graft survival after malignancy. The proportionality assumption for this model was checked by log-log curves.

As this study was a historical cohort one, data were collected from previous medical records in the transplant centers. When the missing clinical variables were high, they were excluded from analysis.

The candidate predictors for including in the model were gender, age, type of cancer, transplantation time until diagnosis (month), age at the time of diagnosis, ALG/ATG, treatment modality, response to treatment, metastasis, CMV infection after cancer, and immunosuppressive regimen.

The definitions of some covariates are:

Type of the cancer: Patients with tumor were categorized into 5 groups according to their type of neoplasm: Non-KS, KS, PTLD, GU and RS tumors, and solid tumors. Non-Kaposi's sarcoma tumors (non-KS) included SCC (squamous cell carcinoma), BCC (basal cell carcinoma), and melanoma. Tumors of breast, ovary and uterine in females, prostate and seminoma in males and renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of bladder in both gender were considered as genitourinary and reproductive system (GU and RS) neoplasms. The term of solid tumors was used for all malignancies except skin tumors, PTLD (posttransplant lymphoproliferative disorder) and GU and RS cancers.

Treatment modality: Treatment modalities were considered according to the type of cancer, staging of disease, and involved organs. Management included a combination of reduction, withdrawal, or changing of the immunosuppressive agents, chemotherapy, radiotherapy, hormone therapy, and surgical resection.

(ATG/ALG): Monoclonal antibody (ATG/ALG) can be required for induction therapy and acute steroid-resistant rejection episodes during the first 3 months following kidney transplantation. Induction therapy with ATG/ALG was used for highly sensitized patients, those receiving kidneys from deceased donors with delayed graft function, patients with poorly matching living donors, and those with the second or more transplants. None of the patients took OKT3.

Immunosuppression protocols: The immunosuppressive therapy was based on cyclosporine/sirolimus, mycophenolate mofetil (MMF)/azathioprine (AZA), and steroids. Before 2000, patients received dual maintenance immunosuppression with prednisone and cyclosporine/AZA or triple therapy with cyclosporine, prednisone, and AZA. Afterwards, the majority of patients received cyclosporine, prednisone, and MMF as well.

4. Results {#sec125143}
==========

The patients with malignancy were followed up after diagnosis of cancer for a median time of 22 months (1 - 168 months). The mean age at the time of diagnosis of cancer was 50.8 ± 13.2 years (range 15.5 - 82.0 years) and the mean interval between transplant and diagnosis of malignancy was 51.08 ± 48.6 months. A total of 180 (67.7%) of recipients were male. The long-term graft loss was seen in 27 (10.2%) cases. [Figure 1](#fig23853){ref-type="fig"} shows graft survival functions for this data. According to [Figure 1](#fig23853){ref-type="fig"}, the 1-year and 2-year graft survival after diagnosis of cancer were 93.6% and 91.7%, respectively.

![Graft Survival Function for Cox Model](ircmj-17-11-20281-i001){#fig23853}

[Table 1](#tbl32324){ref-type="table"} shows the incidence of chronic graft loss in patients with posttransplant malignancies according to covariates. According to [Table 1](#tbl32324){ref-type="table"}, incidence of chronic graft loss was significantly higher in male patients with solid cancers, withdrawal of immunosuppressant, no response to treatment, and metastasis of tumor.

###### Long-term Graft Survival in Patient With Posttransplant Malignancies^[a](#fn33529){ref-type="table-fn"}^

  Variables                                     Total Number   Long-term Graft Loss Number, %   P Value       
  --------------------------------------------- -------------- -------------------------------- ------------- --------
  **Gender**                                                                                                  0.040
  Male                                          180            157 (87.2)                       23 (12.8)     
  Female                                        86             82 (95.3)                        4 (4.7)       
  **Cancer**                                                                                                  0.055
  KS                                            84             74 (88.1)                        10 (11.9)     
  Non-KS                                        57             56 (98.2)                        1 (1.8)       
  PTLD                                          72             65 (90.3)                        7 (9.7)       
  GU & RS                                       25             21 (84.0)                        4 (16.0)      
  Solid                                         28             23 (82.1)                        5 (17.9)      
  **ALG/ATG**                                                                                                 0.110
  No                                            183            168 (91.8)                       15 (8.2)      
  Yes                                           36             30 (83.3)                        6 (16.7)      
  **Treatment modality**                                                                                      0.0001
  Without                                       80             58 (72.5)                        22 (27.5)     
  Decrease                                      74             71 (95.9)                        3 (4.1)       
  Change                                        29             28 (96.6)                        1 (3.4)       
  Unmodified                                    25             24 (96)                          1 (4)         
  **Response to treat**                                                                                       0.02
  No                                            74             60 (81.1)                        14 (18.9)     
  Yes                                           162            149(92)                          13 (8.0)      
  **Metastasis**                                                                                              0.002
  No                                            156            147 (94.2)                       9 (5.8)       
  Yes                                           50             40 (80)                          10 (20.0)     
  **CMV infection after cancer**                                                                              0.801
  No                                            43             37 (86)                          6 (14.0)      
  Yes                                           12             10 (83.3)                        2 (16.7)      
  **Immunosuppressive regimen**                                                                               0.081
  MMF                                           96             91 (94.8)                        5 (5.2)       
  AZA                                           152            134 (88.2)                       18 (11.8)     
  **Age, y**                                    46.2 ± 12.9    46.5 ± 13.07                     43.3 ± 11.4   0.230
  **Transplantation until diagnosis (month)**   51.08 ± 48.6   51.3 ± 47.2                      48.6 ± 60.2   0.790
  **Age at the time of diagnosis, y**           50.8 ± 13.2    51.2 ± 13.1                      47.6 ± 13.8   0.210

^a^Abbreviations: ALG/ATG, Antilymphocyte/antithymocyte globulin; AZA, Azathioprine; CMV, Cytomegalovirus; GU and RS, Genitourinary and Reproductive system; KS, Kaposi's sarcoma; MMF, Mycophenolate mofetil; Non-KS, Non Kaposi's sarcoma; PTLD, Posttransplant lymphoproliferative disorder.

Furthermore, [Table 2](#tbl32325){ref-type="table"} shows the hazard ratios (HR) and standard errors of significant risk factors of graft survival after malignancy by using Cox proportional model. This model indicated that the significant risk factors associated with graft survival are type of the cancer (P \< 0.0001), response to treatment (P \< 0.0001, HR=0.14), metastasis (P \< 0.0001, HR = 5.68), and treatment modality (P = 0.0001). The parallel lines of log-log curves for the level of these variables approved their proportionality assumption. Hazards of graft loss for PTLD and GU and RS cancers were similar to KS cancer. But the hazard of graft loss was higher in solid cancer cases and lower in non-KS cancer cases, compared to KS cancer cases. Hazard of long-term graft loss in unmodified treatment modality was similar to that of patients with withdrawal of immunosuppression (i.e. without group), while change of immunosuppressive drugs or their dose decreases hazards of long-term graft loss versus withdrawal of immunosuppressant. Response to treatment decreased the hazards of graft loss but metastasis of tumor increased this hazard in patients with malignancy ([Table 2](#tbl32325){ref-type="table"}).

###### Factors Associated With Long-term Graft Survival in Patients with Post-transplant Malignancies in Cox Model^[a](#fn33530){ref-type="table-fn"}^

  Variables                   Hazard Ratio    95% CI   P Value   
  --------------------------- --------------- -------- --------- -----------
  **Cancer**                                                     
  KS                          Base Category                      
  Non-KS                      0.11            0.013    0.93      0.042
  PTLD                        1.28            0.482    3.41      0.610
  GU and RS                   2.03            0.62     6.65      0.240
  Solid                       3.62            1.18     11.04     0.020
  **Treatment modality**                                         
  Without                     Base Category                      
  Decrease                    0.122           0.04     0.37      0.001
  Change                      0.12            0.01     0.96      0.040
  Unmodified                  0.16            0.02     1.14      0.070
  **Response to treatment**                                      \< 0.0001
  No                          Base Category                      
  Yes                         0.14            0.06     0.32      
  **Metastasis**                                                 \< 0.0001
  No                          Base Category                      
  Yes                         5.68            2.24     14.42     

^a^Abbreviations: ALG/ATG, Antilymphocyte/Antithymocyte globulin; GU and RS, Genitourinary and Reproductive system; KS, Kaposi's sarcoma; Non-KS, Non Kaposi's sarcoma; PTLD, Posttransplant lymphoproliferative disorder.

[Figure 2](#fig23854){ref-type="fig"} shows graft survival functions for types of cancer. According to [Figure 2](#fig23854){ref-type="fig"}, the patients with non-KS cancer had the lowest hazard of graft loss after diagnosis of cancer (or highest graft survival) and patients with solid cancer had the highest hazard of graft loss (or lowest graft survival).

![Graft Survival Function for Cox Model According to the Types of Cancer](ircmj-17-11-20281-i002){#fig23854}

5. Discussion {#sec125144}
=============

Our study aimed to evaluate the risk factors of graft survival in the recipients with post-transplant malignancy. Evaluating risk factors that change hazards of long-term graft loss, especially in recipients diagnosed with cancer, is an important research goal. For this study, we used data of multicenter study that was conducted by Einollahi et al. They concluded that the skin (52.9%) and PTLD (27%) cancer were the most frequently observed malignancy after renal cancer ([@A20281R21]).

Our study showed that the long-term graft loss was seen in 27 (10.2%) cases. The graft 1-year survival after diagnosis of cancer was 93.6%. Other studies in Iran also reported 1-year survival of graft after kidney transplant as 94.7% ([@A20281R9]), or 85.6% and 97.4% ([@A20281R10]). These 2 survival rate have different definitions, 93.6% is the survival rate after diagnosis of cancer but 94.7% is the survival rate after transplantation. Thus these 2 rates are not comparable.

Errasti et al. concluded in their study that the presence of malignancy in some patients is the main cause of graft failure ([@A20281R17]). In this context, our results indicated that the type of cancer has a significant relationship with graft survival after diagnosis of cancer and solid cancers had the highest hazards to long-term graft loss. Also Dantal and Pohanka found that solid organ cancers, although less common, are associated with a far worse prognosis in renal transplant recipients ([@A20281R22]) that perhaps justified this result.

In some studies, it has been concluded that improvements in immunosuppressive regimens and general care of the kidney transplant recipient have led to significantly enhanced graft survival ([@A20281R23], [@A20281R24]). The results of our study confirmed these findings. Our study showed that decreasing dose or changing of immunosuppressive drugs decreases the hazard of long-term graft loss or prolongs the graft survival after cancer. But Vanhove et al. showed that MMF dose reductions in ≥ 50% did not compromise graft survival ([@A20281R25]).

Also we showed that failure to treatment and metastasis of tumor increase the hazard of long-term graft loss. However, there was no relationship between gender, age, CMW infection, and type of immunosuppressive regimen with survival of graft after cancer. The effects of these factors are different in other studies. Unlike our study, Braun et al. ([@A20281R11]) and Rao et al. ([@A20281R16]) showed in their studies that cytomegalovirus (CMV) infection and other infections were independent risk factors of recipients for graft loss ([@A20281R11], [@A20281R16]). Also Briganti et al. ([@A20281R26]) and Wigmore et al. ([@A20281R27]) showed that older age of the recipient was a predictive factor for reduction of 12-month graft survival. However, similar to our study, Saudan et al. ([@A20281R28]) concluded that graft survival was not different between the two recipient age groups. In addition, Kolonko et al. indicated that risk for graft loss was significantly higher in females ([@A20281R29]).

As this study was retrospective and data have been collected from previous medical records and all contributing factors were not accessible, some missing data and probability of evaluation of only some especial risk factors were two limitations of this study.

Results and findings of this study can guide nephrologists in general care of the kidney transplant recipients. By controlling the modifiable risk factors and the modality of treatment, physicians can provide more effective treatment. For example, in the recipients with solid cancer, no response to treatment, or metastasis of tumor who are at high risk of chronic graft loss, nephrologists can focus on the change of immunosuppressive drugs or decrease their dose to prolong graft survival after diagnosis of cancer.
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